Group items matching

in title, tags, annotations or url

TRANSLATIONAL MEDICINE AND THERAPEUTICS: The goal of the PhRMA Foundation's Translational Medicine and Therapeutics Program is to promote the development and use of experimental and computational methods in an integrative approach towards clinical needs in diagnosis, treatment and prevention. This can involve enhanced understanding of human biological and disease processes but requires a strong translational component. This program will support the concepts of Translational Medicine and Therapeutics as defined by the Foundation: "Translational medicine and therapeutics is a discipline focused on bridging experimental and computational technologies and discoveries in the research laboratory to their application in clinical practice. Examples of research components include activities in molecular and cellular biology, pathophysiology, systems biology, bioinformatics, modeling and simulation, and other quantitative sciences to connect basic biological concepts and entities to directly address unmet medical needs. The goals are to use clinical observation as the basis for hypothesis generation to further basic research and to efficiently advance the product of basic research to patients." Translational Medicine and Therapeutics awards will advance training and support career development of scientists engaged in research that significantly integrates cutting-edge technologies with advanced biological, chemical, and pharmacological sciences and engineering methodologies in such areas as (but not restricted to): * Genetics (Molecular, Pharmaco-, Population, Medical) * Genomics (Functional, Structural, Toxico-, Pharmaco-, Comparative) * Systems (Biology and Pharmacology) * Pathways and networks * Integrative biology * Modeling and simulation * Target Identification and Validation * Biomarker Discovery and Validation * Vaccine Development * Molecular Epidimiology * Imaging * Disease Modeling

The National Multiple Sclerosis Society mobilizes people and resources to drive research for a cure and to address the challenges of people affected by MS. To that end, the society is accepting applications for its Pilot Grant Program, which provides high-risk pilot grants for the testing of novel ideas that may serve to advance its mission of stopping MS progression, restoring function, improving quality of life, and preventing MS. The program supports fundamental as well as applied studies, non-clinical or clinical in nature, including projects in patient management, care, and rehabilitation.

This Request for Proposal (RFP) seeks to support the development and validation of novel and existing biomarkers that will enhance the design and performance of clinical trials for Alzheimer's disease, related dementias, and cognitive aging. More accurate and comprehensive biomarkers will improve patient selection and pharmacodynamic measurements, and provide additional tools for early detection and accurate diagnosis.

This program will address the clinical research mission of the National Institutes of Health (NIH) and will lead to better treatments for disease and to improvements in human health.  The NIH funds research and research training at extramural institutions, as well as within the NIH Intramural Research Program (IRP) to address this goal.  However, these efforts can be hindered by barriers to clinical and translational research.  Such barriers include limited research time for clinical investigators, increases in the length of time to independent careers, and access to hospital facilities and patient enrollments. In an effort to address those barriers, the NIH has created the Lasker Clinical Research Scholars (Lasker Scholars) program that will offer applicants the opportunity to compete for a unique combination of intramural and extramural resources for clinical research. The program will support a small number of exceptional clinical researchers in the early stages of their careers to promote their development to fully independent scientists.  The program combines a period of research experience as a tenure-track Investigator in the IRP with additional years of independent financial support, either within the IRP or at an extramural research institution. The Scholar must meet the conditions described below, including fulfilling milestones and agreement with IRP, in order to receive the additional years of funding.

The specific objective of the "E-Rare-3" call is to promote clinical and pre-clinical proof of concept studies for the potential application of medicinal products that are either already marketed or have achieved a significant stage in the development process in rare indications. Projects should aim at discovering new therapeutic uses for agents whose clinical safety has already been characterized to move quickly into proof of concept trials in the selected rare diseases' patient population.

The mission of the 2017 Global ASPIRE Young Investigator Research Awards in Endocrinology is to advance the medical knowledge of the fundamental mechanisms of disease, mechanisms of action of current and potential future treatments, and to improve the care of patients with endocrine disorders.

Research into the etiology and pathophysiology of PD has identified an increasing number of genetic and cellular targets where therapeutic intervention could benefit people with PD, including: Epidemiological studies that have identified both protective and risk factors for PD. Genetic studies that have implicated candidate genes whose protein products may underlie PD pathogenesis. Biochemical studies from cellular and whole organism model systems that point to biological pathways important in PD etiology and pathogenesis, as well as examination of cell death and trophic factor signaling pathways that have pointed to potential protective targets. Emerging understanding of dopamine neuronal development and maintenance in adulthood that has provided potential targets to restore/protect dopaminergic function in PD patients. Improved understanding of the neurochemistry and neurophysiology of the basal ganglia and related neuronal circuits that have suggested ways to alter neuronal function that could help treat motor and non-motor symptoms of PD not addressed by current therapeutics. Better understanding of the physiological and molecular pathways underlying treatment-induced complications that have revealed potential targets for interventions to ameliorate these troubling side effects.

The purpose of this FOA is to support research to deepen our knowledge of the use of synthetic psychoactive drugs, their mechanisms of action, their health effects, and development of prevention strategies and strategies to treat patients in emergency departments and long range treatment.

The purpose of this FOA is to support research to deepen our knowledge of the use of synthetic psychoactive drugs, their mechanisms of action, their health effects, and development of prevention strategies and strategies to treat patients in emergency departments and long range treatment.

The purpose of this FOA is to support research to deepen our knowledge of the use of synthetic psychoactive drugs, their mechanisms of action, their health effects, and development of prevention strategies and strategies to treat patients in emergency departments and long range treatment.

Research Awards provide grant support to both new and established investigators. Basic Science Awards are designed to support basic science research in any area relevant to the etiology or pathophysiology of diabetes and its complications, while Clinical Science and Epidemiology Awards support patient-oriented clinical research and epidemiology research in diabetes. The Translational Science Award supports research that accelerates the transition of scientific discoveries into clinical applications. Innovation Awards are intended to support creative proposals that may lack preliminary data but hold significant promise for advancements in the prevention, cure or treatment of diabetes.

The purpose of this Funding Opportunity Announcement (FOA) is to establish a centralized DNA Sequencing Core for Undiagnosed Diseases Network (UDN) patients.

The Jerome Lejeune Foundation is the world's oldest and largest private funder of research into treatments for intellectual disabilities of genetic origin, especially, but not limited to, Down syndrome. The Foundation's specific research interest is to discover a means of  treating genetic intellectual disabilities in order to improve the memory, speech, and cognition of patients. Researchers who are working in basic or applied science and who have genetic intellectual disabilities (Down syndrome, Fragile X syndrome, Cri-du-Chat syndrome, rare chromosomal anomalies, Rett syndrome, Williams Beuren, Willi Prader, Angelman…) as their therapeutic target  are invited to submit proposals for funding assistance from the Foundation.

The Kure It-AACR Grant for Kidney Cancer Research represents a joint effort to promote and support innovative cancer research. This grant is available to full time, independent junior and senior investigators to develop and study new ideas and innovative approaches that have direct application and relevance to kidney cancer patients. Applicants with experience in other areas of cancer or biomedical/health science research who have promising ideas and approaches that can be applied to kidney cancer research are encouraged to apply.

The Arthritis Foundation is requesting letters of interest (LOI) for research projects that show promise to achieve a faster cure for arthritis and related diseases. The LOI will inform the development of a new Scientific Strategy to be announced in November 2014 and a Request for Proposals (RFP) to be released in December 2014. The Arthritis Foundation is particularly interested in research regarding fact-based metrics to guide actions and policies to improve the health of people across the lifespan with arthritis and related diseases; expediting movement between basic research to patient-centered research to population-based research to point of care; and improving clinical decision-making and health outcomes at point of care through the use of new products, tools, and technologies for people across the lifespan with arthritis and related diseases.

Reliable, efficient laboratory services and networks are fundamental components of effective, well-functioning health systems and are essential for patient management, disease detection and control and surveillance. The purpose of this funding opportunity announcement (FOA) is to support the Ministry of Health in Mozambique to strengthen the integrated national laboratory network in order to ensure the provision of quality laboratory services for clinical diagnosis, screening, research, and surveillance to support HIV care and treatment and the achievement of an AIDS free generation. The FOA will address the following cross-cutting elements of laboratory systems: governance and management of the integrated laboratory network, strengthening institutions to build and retain a quality laboratory workforce, and building technical and scientific capacity and implementing quality management systems towards accreditation. The expected project outcomes include:* Increased efficiency of laboratory network operations* Increased implementation of quality management systems through a technically and financially sustainable quality improvement and accreditation program owned and implemented by the Ministry of Health* An increase in the coverage and quality of external quality assessment (EQA) services* Improved adherence to laboratory biosafety standards* Improved quality of laboratory pre-service training * Increase in number of laboratory managers and leaders with Master's level training* Improved capacity of laboratory workforce and decreased reliance on external training support

The Ministry of Health (MOH) in Burma and the National Department of Health (NDOH) in Papua New Guinea (PNG) plan to rapidly expand high-quality antiretroviral treatment (ART) coverage in the coming years by increasing capacity at existing delivery sites and decentralizing selected services to provincial, district and township levels. In order to accomplish this expansion, the MOH and NDOH need strong laboratory systems that ensure high-quality HIV diagnostic and clinical monitoring of patients at the existing and new service delivery sites. This will require strengthening the capacity of Burma's National Health Laboratory (NHL) and Papua New Guinea's Central Public Health Laboratory (CPHL), as well as building capacity of sub-national laboratories and improving the laboratory network in these countries.This Funding Opportunity Announcement (FOA) will be awarded to a technical assistance (TA) partner to provide support to NHL and CPHL in several key areas, including: (1) developing and helping implement standard operating procedures, policies, guidelines, and training materials related to management and operations of national and sub-national laboratories; (2) building capacity of NHL and CPHL staff to validate, conduct, and ensure strong (and often cross-cutting) quality assurance and monitoring systems for HIV-related diagnostic and clinical monitoring activities; (3) strengthening the overall laboratory network in Burma and PNG that may include specimen transport and right-sizing of various classes of laboratories; and (4) providing supporting mentoring of NHL and NDOH staff and opportunities for professional development.

The intent of the CVGPS is to converge these vast repositories of clinical and genomic data and add on other diverse population studies, established and proposed, to create a database unique in scale, diversity, and potential for gleaning new insights. The CVGPS will consolidate disease state and patient-specific data with a bio bank of molecular information from tissue samples meticulously stored, in some cases for decades, from participating population studies. These phenotypic and genotypic resources will be made available to researchers within an integrated network, with strict controls on database security and integrity. The ongoing growth of this network of cardiovascular studies will add to the initiative's value and opportunities for innovation. 

Two $60,000 pilot grants are available for Lymphangioleiomyomatosis (LAM) research. Focus is on translational proposals with strong likelihood of future federal funding, that use LAM samples, models or patient data, and which have the potential to favorably impact human health will be given priority. Examples of desirable topic areas include identification of molecular targets, biomarker development, and biomarker driven small pilot trials

Botswana has both a high prevalence of HIV (25% among persons 15-49 years of age) and a high incidence of TB (455 new cases per 100,000 population per year). Drug resistance is a concern with both diseases. High quality surveillance and monitoring data are needed for effective disease control efforts. This funding opportunity announcement (FOA) has two primary objectives. Both are meant to support ongoing efforts of the Botswana Ministry of Health (MOH). The first objective is to strengthen the capacity of the TB laboratory and surveillance systems focusing on drug resistance and system integration. The second objective is to a) complete the national rollout of PIMS II (Patient Information Management System) to health care facilities and development of the national data warehouse and b) to support development and implementation of an HIV surveillance strategy at national- and district-levels.